Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Magnesium picolinate compositions and methods of use

A technology of magnesium picolinate and picolinic acid, which can be used in drug combination, drug delivery, pharmaceutical formulation, etc., and can solve problems such as shortage

Active Publication Date: 2019-07-23
JDS THERAPEUTICS
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this preparation of MgPic lacks certain features required to make it useful in today's pharmaceutical and / or nutraceutical applications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Magnesium picolinate compositions and methods of use
  • Magnesium picolinate compositions and methods of use
  • Magnesium picolinate compositions and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1: Attempt to prepare magnesium picolinate according to Swiderski

[0101] According to Swiderski, MgPic can be prepared by the exchange reaction of magnesium sulfate and barium picolinate. Therefore, a barium picolinate solution was prepared by dissolving 2 molar equivalents of picolinic acid and 1 molar equivalent of barium hydroxide in 100 mL of water. When a clear solution of barium picolinate was obtained, 1 molar equivalent of magnesium sulfate powder was added. After stirring for 12 h, the slurry was filtered to remove solid barium sulfate, the filtrate was concentrated to dryness, and the resulting solid was dried at 120 °C for 24 h to obtain anhydrous MgPic. The barium level in the anhydrous MgPic was found to be greater than 200 ppm. This far exceeds the drug tolerance of about 200 ppm barium contamination. Repeated dissolution and crystallization attempts to reduce barium contamination levels resulted in a loss of almost 50% of the MgPic and failed...

Embodiment 2

[0102] Example 2: Preparation A of crystalline and amorphous magnesium picolinate

[0103] Picolinic acid (3.7 g, 30 mmol) and magnesium acetate tetrahydrate (3.2 g, 15 mmol) were suspended in 25 mL of water. The slurry was stirred and heated at reflux overnight, then filtered to isolate 1.7 g of crystalline MgPic. The remaining filtrate was cooled and evaporated to dryness, affording an additional 2.2 g of amorphous MgPic with traces of residual acetate. Acetate was removed by washing the solid with ethanol to provide MgPic (crystalline and amorphous) in 96% overall yield. product of 1 H-NMR spectrum ( figure 2 ) and the spectrum of picolinic acid metal salt Figure 1 Sincerely. The product is readily soluble in water and provides a clear and colorless MgPic solution. This product contains acceptable traces of barium and other heavy metals at levels of less than 200ppm for each element tested. Accordingly, embodiments of the MgPic composition may contain less than abo...

Embodiment 3

[0104] Embodiment 3: Preparation B of crystalline magnesium picolinate

[0105] Picolinic acid (1.23 g, 10 mmol) was added to 25 mL of ethanol and stirred at room temperature until complete dissolution was observed. Magnesium ethoxide (560 mg, 4.9 mmol) was added and the slurry was heated to 80°C. Water was added dropwise until a clear solution was obtained. The solution was filtered while hot, allowed to cool to room temperature, and then kept at 4°C overnight. The resulting white crystals were isolated by filtration, washed with ethanol, and air-dried to afford 1.1 g of crystalline MgPic in 85% yield. product of 1 H-NMR spectrum ( image 3 ) and the spectrum of picolinic acid metal salt Figure 1 Sincerely. This product contains acceptable traces of barium and other heavy metals at levels of less than 200ppm for each element tested.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.

Description

[0001] field of invention [0002] The present application relates to magnesium picolinate (MgPic) compositions and methods of use thereof. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency. Background technique [0003] Magnesium is an abundant mineral that occurs naturally in the body and in many foods, but the compositions disclosed herein do not occur naturally, and existing synthetic methods, as further described herein, fail to produce adequate compositions. Magnesium is an essential cofactor in many physiological processes, including energy production, protein synthesis and transport, cell signaling and homeostasis. In fact, magnesium exhibits biological activity in all cells and tissues of the body. [0004] Dietary magnesium can be obtained from milk, oatmeal, fruits, vegetables, nuts and seeds. Magnesium uptake occurs primarily in the sma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K33/06A61P1/00
CPCA61K33/06A61K31/4402A61P1/00A61P1/14A61P11/06A61P13/12A61P19/10A61P21/00A61P25/00A61P25/04A61P25/06A61P25/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/24A61P25/28A61P29/00A61P29/02A61P3/00A61P3/02A61P3/10A61P39/02A61P43/00A61P9/00A61P9/10A61P9/12A61K9/0053A61K9/0019A61K9/28A61K9/2846
Inventor J·R·科莫罗夫斯基D·J·尼尔森
Owner JDS THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com